Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
Price:
35.69
CNY
0.54%
Market Closed
Market Cap:
¥5.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
|
CN |
|
Hormel Foods Corp
NYSE:HRL
|
US |
|
H
|
Hunan Aihua Group Co Ltd
SSE:603989
|
CN |
|
R
|
Raiffeisen Bank International AG
VSE:RBI
|
AT |
|
T
|
Thorne Healthtech Inc
F:F7G
|
US |
|
Aukett Swanke Group PLC
LSE:AUK
|
UK |
|
Akshar Spintex Ltd
NSE:AKSHAR
|
IN |
|
Sinocelltech Group Ltd
SSE:688520
|
CN |
|
C
|
Creative Global Technology Holdings Ltd
NASDAQ:CGTL
|
HK |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
US |
|
Mattel Inc
NASDAQ:MAT
|
US |
|
S
|
Scout Gaming Group AB
STO:SCOUT
|
SE |
|
F
|
Ferrocarril del Pacifico SA
SGO:FEPASA
|
CL |
|
UUUM Co Ltd
TSE:3990
|
JP |
Multiples-Based Value
The Multiples-Based Value of one
Beijing Konruns Pharmaceutical Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 35.69 CNY,
Beijing Konruns Pharmaceutical Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Beijing Konruns Pharmaceutical Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Beijing Konruns Pharmaceutical Co Ltd Competitors
Beijing Konruns Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
|
5.7B CNY | 6.5 | 99.6 | 132.4 | 132.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
577.7B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10 | 12.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20.2 | 7.8 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.6B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
